| Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study M Alavi, J Grebely, M Micallef, AJ Dunlop, AC Balcomb, CA Day, ... Clinical Infectious Diseases 57 (suppl_2), S62-S69, 2013 | 140 | 2013 |
| Continued low uptake of treatment for hepatitis C virus infection in a large community‐based cohort of inner city residents M Alavi, JD Raffa, GD Deans, C Lai, M Krajden, GJ Dore, MW Tyndall, ... Liver International 34 (8), 1198-1206, 2014 | 120 | 2014 |
| Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia M Alavi, MG Law, H Valerio, J Grebely, J Amin, B Hajarizadeh, C Selvey, ... Journal of hepatology 71 (2), 281-288, 2019 | 112 | 2019 |
| The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: an international study M Alavi, NZ Janjua, M Chong, J Grebely, EJ Aspinall, H Innes, HM Valerio, ... Journal of hepatology 68 (3), 393-401, 2018 | 95 | 2018 |
| Chronic hepatitis C burden and care cascade in Australia in the era of interferon‐based treatment B Hajarizadeh, J Grebely, H McManus, C Estes, H Razavi, RT Gray, ... Journal of gastroenterology and hepatology 32 (1), 229-236, 2017 | 88 | 2017 |
| Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study J Grebely, M Alavi, M Micallef, AJ Dunlop, AC Balcomb, N Phung, ... Addiction 111 (2), 311-319, 2016 | 83 | 2016 |
| Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users J Grebely, GV Matthews, M Hellard, D Shaw, I Van Beek, K Petoumenos, ... Journal of hepatology 55 (1), 76-85, 2011 | 83 | 2011 |
| Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage Study H Valerio, M Alavi, D Silk, C Treloar, M Martinello, A Milat, A Dunlop, ... Clinical Infectious Diseases 73 (1), e69-e78, 2021 | 73 | 2021 |
| Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C M Alavi, T Spelman, GV Matthews, PS Haber, C Day, I van Beek, N Walsh, ... International Journal of Drug Policy 26 (10), 976-983, 2015 | 60 | 2015 |
| Global elimination of hepatitis C virus by 2030: why not? GJ Dore, M Martinello, M Alavi, J Grebely Nature medicine 26 (2), 157-160, 2020 | 57 | 2020 |
| Effect of pegylated interferon‐α‐2a treatment on mental health during recent hepatitis C virus infection M Alavi, J Grebely, GV Matthews, K Petoumenos, B Yeung, C Day, ... Journal of gastroenterology and hepatology 27 (5), 957-965, 2012 | 55 | 2012 |
| Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014) R Waziry, J Grebely, J Amin, M Alavi, B Hajarizadeh, J George, ... Journal of hepatology 65 (6), 1086-1093, 2016 | 51 | 2016 |
| Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study M Alavi, MG Law, J Grebely, J Amin, B Hajarizadeh, J George, GJ Dore Journal of hepatology 65 (5), 879-887, 2016 | 47 | 2016 |
| Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development H Samji, A Yu, M Kuo, M Alavi, R Woods, M Alvarez, GJ Dore, M Tyndall, ... Journal of hepatology 67 (5), 909-917, 2017 | 43 | 2017 |
| Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment EJ Aspinall, SJ Hutchinson, NZ Janjua, J Grebely, A Yu, M Alavi, J Amin, ... Journal of hepatology 62 (2), 269-277, 2015 | 42 | 2015 |
| High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia H Valerio, M Alavi, M Law, S Tillakeratne, J Amin, NZ Janjua, M Krajden, ... Journal of Hepatology 74 (2), 293-302, 2021 | 41 | 2021 |
| An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study M Alavi, H Poustchi, S Merat, S Kaveh-Ei, A Rahimi-Movaghar, B Shadloo, ... International Journal of Drug Policy 72, 99-105, 2019 | 41 | 2019 |
| Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta‐analysis MT Yousafzai, S Bajis, M Alavi, J Grebely, GJ Dore, B Hajarizadeh Journal of viral hepatitis 28 (10), 1340-1354, 2021 | 39 | 2021 |
| The contribution of health risk behaviors to excess mortality in American adults with chronic hepatitis C: A population cohort‐study H Innes, A McAuley, M Alavi, H Valerio, D Goldberg, SJ Hutchinson Hepatology 67 (1), 97-107, 2018 | 36 | 2018 |
| Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications JA Kwon, GJ Dore, B Hajarizadeh, M Alavi, H Valerio, J Grebely, R Guy, ... PLoS One 16 (9), e0257369, 2021 | 34 | 2021 |
Jason GrebelyProfessor, The Kirby Institute, UNSW SydneyEmail verificata su kirby.unsw.edu.au